TCR2 Therapeutics Inc.
Compositions and methods for TCR reprogramming using fusion proteins
Last updated:
Abstract:
Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
Status:
Grant
Type:
Utility
Filling date:
10 Aug 2020
Issue date:
10 Aug 2021